6 results
Primary Objective: - to evaluate the pharmacokinetic (PK) parameters (AUC0-t, AUC0-inf, Cmax, C24hr, Tmax, and apparent t*) of MK-3682 and its circulating metabolites (IDX20664 and IDX23267), MK-5172, and MK-8742 following administration of two…
Primary ObjectiveTo evaluate and compare the pharmacokinetic (PK) parameters (AUC0-t, AUC0-inf, Cmax, C24hr, Tmax, and apparent t*) of MK-3682 and its circulating metabolites MK-5172, and MK-8742 following administration of three test premarket…
Primary Objective: The primary objective of the study is to assess long-term safety of AMG 108 (125 mg, 250 mg) SC in subjects with RA previously enrolled in study 20050168.Secondary Objective(s): The secondary objectives of the study are:* To…
In this study we would like to investigate whether cerebral perfusie and cerebral metabolism can be influenced with pharmacological agents in patients with MS and in healthy control persons. Cerebral perfusion and cerebral metabolism wil be measured…
The primary objectives of this study are:Part A 1. To characterize the effects of single doses of beta-adrenoceptor (*-AR) agonists CST-101, CST-103 and * AR partial agonist CST-109 on the functional domains of the central nervous system (CNS), as…
To determine if short-term treatment with the selective beta-2-adrenergic agonist clenbuterol improves glucose disposal via the mTORC2 pathway in lean, healthy male individuals with normal physical activity